Journey Medical Corp

Journey Medical Corp. operates as a commercial-stage pharmaceutical company, which engages in developing, acquiring, licensing and commercializing of dermatology products. It s focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its sales and marketing model. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Journey Medical Corp reports revenue growth and profitability in Q1

Journey Medical Corp's Q1 2024 performance reflects revenue growth and profitability driven by key products and cost management.
The company's strengths lie in the success of DFD-29, financial stability, and strategic business development initiatives.
Challenges include maintaining market share, successful DFD-29 launch, and balancing new product pursuits with existing offerings.
Opportunities include leveraging DFD-29 for sustained profitability, exploring new product opportunities, and expanding global presence.

Journey Medical Corp (DERM) reports robust Q2 results and eyes FDA approval for growth

Journey Medical Corp (DERM) demonstrated strong revenue performance and cost management in Q2 2024, positioning for future growth.
The company's focus on innovation, IP protection, and financial discipline bodes well for long-term sustainability and profitability.
Despite challenges in a competitive market, Journey Medical Corp (DERM) remains optimistic about FDA approvals and revenue diversification.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Journey Medical's (DERM) phase I study, assessing the impact of DFD-29 on the microbial flora of healthy adults, obtains its primary endpoints.

Journey Medical (DERM) Up on Rosacea Candidate's Positive Data

Fortress Biotech

Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

Journey Medical Corp (NASDAQ:DERM ) Q1 2023 Earnings Conference Call May 22, 2023 4:30 PM ET Company Participants Matt Blazei - CORE IR Claude Maraoui - Founder, President and CEO Joseph Benesch - Interim CFO Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Journey Medical's First Quarter 2023 Financial Results and Corporate Update Conference Call.

Journey Medical Corp (DERM) Q1 2023 Earnings Call Transcript

Journey Medical Corporation (DERM) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.08 per share a year ago.

Journey Medical Corporation (DERM) Reports Q1 Loss, Lags Revenue Estimates

Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023 Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29 Company to hold conference call on May 22, 2023, at 4:30 p.m. ET SCOTTSDALE, Ariz.

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Company to host conference call to discuss financial results and provide a corporate update on May 22, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 22, 2023 at 4:30 p.m. ET

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

Company to host conference call to discuss financial results and provide a corporate update on May 11, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 11, 2023 at 4:30 p.m. ET

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

Journey Medical Corp (NASDAQ:DERM ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Matt Blazei - CORE IR Claude Maraoui - Founder, President, CEO & Director Joseph Benesch - Interim CFO Srinivas Sidgiddi - VP, Clinical Development & Medical Affairs Conference Call Participants Brandon Folkes - Cantor Fitzgerald Scott Henry - ROTH MKM Partners Andrew Fleszar - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by.

Journey Medical Corp (DERM) Q4 2022 Earnings Call Transcript

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -62.16% and 4.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical Corporation (DERM) Reports Q4 Loss, Misses Revenue Estimates

Generated record total revenues of $73.7 million for the full year 2022

Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Company to host conference call to discuss financial results and provide a corporate update on March 29, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 29, 2023 at 4:30 p.m. ET

Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023

Subjects completed 16-week treatment with no significant safety issues

Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

SCOTTSDALE, Ariz., March 07, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that management will participate in the 35th Annual ROTH Conference, which is being held March 12-14, 2023.

Journey Medical Corporation to Participate in the 35th Annual ROTH Conference

SCOTTSDALE, Ariz., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Ernest (Ernie) De Paolantonio has notified the Company that, effective January 27, 2023, he will step down as Chief Financial Officer of Journey Medical to pursue another opportunity. The Company also today announced the appointment of Joseph M. Benesch as Interim Chief Financial Officer, effective January 27, 2023.

Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

Topline data expected in the first half of 2023 Topline data expected in the first half of 2023

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Phase 3, registrational studies remain on track for first half of 2023 topline data readout Phase 3, registrational studies remain on track for first half of 2023 topline data readout

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29

SCOTTSDALE, Ariz., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical's management team will participate in the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference, which is being held on Thursday, December 8, 2022 in Miami, FL.

Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

Journey Medical Corporation (NASDAQ:DERM ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Blazei – CORE IR Claude Maraoui – Co-Founder, President and Chief Executive Officer Ernie De Paolantonio – Chief Financial Officer Ramsey Alloush – General Counsel Conference Call Participants Scott Henry – ROTH Capital Brandon Folkes – Cantor Fitzgerald Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the Journey Medical's Third Quarter 2022 Financial Results and Corporate Update Conference Call.

Journey Medical Corporation (DERM) Q3 2022 Earnings Call Transcript

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -67.65% and 11.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical Corporation (DERM) Reports Q3 Loss, Misses Revenue Estimates

Revenue for the first nine months of 2022 increased 26% to $57.7 million versus the same period in 2021 of $45.6 million

Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30 p.m. ET

Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022

SCOTTSDALE, Ariz., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will participate in two upcoming investor conferences.

Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Journey Medical Corporation (NASDAQ:DERM ) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Claude Maraoui - Co-Founder President and Chief Executive Officer Ernest De Paolantonio - Chief Financial Officer Ramsey Alloush - General Counsel Dr. Srinivas Sidgiddi - Vice President of Clinical Development and Medical Affairs Jules Abraham - IR, CORE IR Conference Call Participants Brandon Folkes - Cantor Fitzgerald Mayank Mamtani - B. Riley FBR Operator Ladies and gentlemen, thank you for standing by.

Journey Medical Corporation (DERM) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -72% and 13.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Journey Medical Corp Stock (DERM)